Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Gilead Sciences
Biotech
After buyout, Gilead is laying off Arcellx staff on both coasts
With Gilead's $7.8 billion buyout of Arcellx complete, the California pharma is consolidating some of the workforce at the acquired company.
Fraiser Kansteiner
May 5, 2026 3:12pm
Gilead loosens ties to Arcus as TIGIT dream ends in ph. 3 fail
Apr 21, 2026 3:07am
Gilead pays Kymera $45M for preclinical protein degrader
Apr 9, 2026 8:45am
After 3 acquisitions, Gilead shifts focus to expanded pipeline
Apr 8, 2026 4:00am
Gilead pays $3.1B for Tubulis to bolster oncology ADC pipeline
Apr 7, 2026 8:30am
Gilead cancels HIV trial as clinical hold remains intact
Apr 1, 2026 4:50pm
